Sunshine Biopharma Capital Expenditures (CapEx) Growth & History (SBFM)
Sunshine Biopharma's capital expenditures (capex) was $174,491 for fiscal 2025.
View full Sunshine Biopharma company overviewSunshine Biopharma annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $174,491 | −$1.5M | −89.47% |
| 2024 | 2024-12-31 | $1.7M | $1.6M | +1914.63% |
| 2023 | 2023-12-31 | $82,251 | −$111,731 | −57.60% |
| 2022 | 2022-12-31 | $193,982 | $193,982 | — |
| 2021 | 2021-12-31 | $0 | −$1,191 | — |
| 2020 | 2020-12-31 | $1,191 | $331 | +38.49% |
| 2019 | 2019-12-31 | $860 | −$17,990 | −95.44% |
| 2018 | 2018-12-31 | $18,850 | $15,132 | +406.99% |
| 2017 | 2017-12-31 | $3,718 | $279 | +8.11% |
| 2016 | 2016-12-31 | $3,439 | −$1,354 | −28.25% |
| 2015 | 2015-12-31 | $4,793 | $4,793 | — |
| 2014 | 2014-12-31 | $0 | — | — |
Sunshine Biopharma quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7,015 | −$152,985 | −95.62% |
| Q1 2026 | 2026-03-31 | $5,129 | −$2,361 | −31.52% |
| Q4 2025 | 2025-12-31 | $1,039 | −$101,561 | −98.99% |
| Q3 2025 | 2025-09-30 | $8,040 | −$508,965 | −98.44% |
| Q2 2025 | 2025-06-30 | $160,000 | −$814,513 | −83.58% |
| Q1 2025 | 2025-03-31 | $7,490 | −$55,447 | −88.10% |
| Q4 2024 | 2024-12-31 | $102,600 | $47,628 | +86.64% |
| Q3 2024 | 2024-09-30 | $517,005 | $507,371 | +5266.46% |
| Q2 2024 | 2024-06-30 | $974,513 | $813,763 | +506.23% |
| Q1 2024 | 2024-03-31 | $62,937 | −$115,458 | −64.72% |
| Q4 2023 | 2023-12-31 | $54,972 | −$139,010 | −71.66% |
| Q3 2023 | 2023-09-30 | $9,634 | $9,634 | — |
| Q2 2023 | 2023-06-30 | $160,750 | $160,750 | — |
| Q1 2023 | 2023-03-31 | $178,395 | $178,395 | — |
| Q4 2022 | 2022-12-31 | $193,982 | — | — |
| Q3 2022 | 2022-09-30 | $0 | — | — |
| Q2 2022 | 2022-06-30 | $0 | — | — |
| Q1 2022 | 2022-03-31 | $0 | — | — |
| Q3 2020 | 2020-09-30 | $800 | $315 | +64.95% |
| Q4 2019 | 2019-12-31 | $860 | −$7,660 | −89.91% |
| Q3 2019 | 2019-09-30 | $485 | −$4,515 | −90.30% |
| Q2 2019 | 2019-06-30 | $485 | −$17,102 | −97.24% |
| Q1 2019 | 2019-03-31 | $0 | −$4,783 | — |
| Q4 2018 | 2018-12-31 | $8,520 | $4,802 | +129.16% |
| Q3 2018 | 2018-09-30 | $5,000 | −$17,295 | −77.57% |
| Q2 2018 | 2018-06-30 | $17,587 | −$4,708 | −21.12% |
| Q1 2018 | 2018-03-31 | $4,783 | $4,783 | — |
| Q4 2017 | 2017-12-31 | $3,718 | $2,622 | +239.23% |
| Q3 2017 | 2017-09-30 | $22,295 | $22,295 | — |
| Q2 2017 | 2017-06-30 | $22,295 | $19,952 | +851.56% |
| Q1 2017 | 2017-03-31 | $0 | $0 | — |
| Q4 2016 | 2016-12-31 | $1,096 | — | — |
| Q3 2016 | 2016-09-30 | $0 | — | — |
| Q2 2016 | 2016-06-30 | $2,343 | — | — |
| Q1 2016 | 2016-03-31 | $0 | — | — |
Sunshine Biopharma capital expenditures (capex) trends
Over the last five fiscal years, Sunshine Biopharma's capital expenditures (capex) increased from $1,191 to $174,491, a change of $173,300. The latest reported quarter, Q2 2026, shows $7,015.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sunshine Biopharma source filings ↗